24 Jun 2017
Two new papers show how rare genetic mutations are helping scientists understand more about the processes that go wrong in the amyotrophic lateral sclerosis/frontotemporal dementia (ALS/FTD) spectrum. A hallmark of these diverse conditions is the abnormal clumping of the nuclear protein TDP-43 in the cytoplasm. In the June 6 Nature Communications, researchers led by David Kang, University of South Florida, Tampa, reported that mutations in the mitochondrial protein CHCHD10 induced TDP-43 translocation from the nucleus to the cytoplasm and poisoned mitochondria and synapses. In a second paper, Yongchao Ma and colleagues from Northwestern University Feinberg School of Medicine, Chicago, debut a new ALS gene, UBQLN4, identifying a variant in a woman with familial ALS. Their paper, published May 2 in eLIFE, shows that the D90A substitution in the ubiquilin impairs proteasome function and causes abnormal sprouting and branching of motor axons in model systems. The results further highlight the role of protein homeostasis in neuronal health and disease.
Kangs intriguing work suggests that wild-type CHCHD10 maintains TDP-43 nuclear localization and protects against TDP-43 toxicity, while disease-related mutations of CHCHD10 have opposite, damaging effects, said Ronald Klein, Louisiana State University Health in Shreveport. The work also adds significantly to the importance of mitochondrial function in neurodegenerative diseases, Klein wrote in an email toAlzforum.
The discovery, just over two years ago, of mutations in the mitochondrial protein CHCHD10 (short for coiled-coil-helix-coiled-coil-helix domain containing protein 10) in several families with amyotrophic lateral sclerosis/ frontotemporal dementia (ALS-FTD) suggested for the first time that dysfunction in the organelles, the cells power plants, could cause motor neuron disease (see Jun 2014 newsand Oct 2014 news).Scientists know little about the function of CHCHD10, which sits inside the mitochondria as part of a protein complex that stabilizes cristae, the organelles membrane folds. In patients with ALS-associated CHCHD10 mutations, mitochondria appear disorganized and dysfunctional (Genin et al., 2015).
Kang set out to understand how CHCHD10 mutations affect protein function, and whether they also impact TDP-43 accumulation and toxicity. To get at those issues, the researchers first turned to the roundworm Caenorhabditis elegans, whose single CHCHD10 homolog, har-1, includes both the arginine-15 (R15) and serine-59 (S59) residues that are mutated in ALS/FTD. Co-first author Courtney Trotter found that har-1 knockouts developed movement problems similar to those seen in worms overexpressing TDP-43. The animals crawled more slowly on an agar plate, and curled up when dropped in liquid, rather than thrashing about like wild-type worms. Their mitochondria appeared to be in poor health. They produced more superoxide than mitochondria from normal worms. Introducing a human CHCHD10 transgene into the har-1 knockouts completely normalized their behaviorthe transgenic worms crawled and swam normally, and their mitochondrial superoxide hovered at control levels. In contrast, human CHCHD10 bearing either the R15L or S59L mutation did not compensate at all, suggesting that the mutations caused a loss of CHCHD10function.
As the two other first authors, Jung-A. Woo and Tian Liu, worked their way through studies on mammalian cells, primary neurons, and finally mouse brains in vivo, they saw the same pattern. Loss of CHCHD10 function, either by knockdown or by overexpression of mutated protein, spelled trouble for mitochondria, disrupting their structure, increasing superoxide production, and causing expression of mitochondrial genes to decrease by half. In primary mouse hippocampal neurons, CHCHD10 mutant expression led to a 50 percent reduction in synaptic markers drebrin and synatophysin as visualized by confocal microscopy. All told, the results suggest the loss of CHCHD10 function in these models poisons mitochondria and zaps synapses.Does any of this affect TDP-43? In the primary neurons, TDP43 exclusively localized to the nucleus, but after knockdown of CHCHD10 or expression of the mutants, a fraction of the TDP-43 moved to the cytoplasm, reaching as far as neuritic processes. Expression of CHCHD10 mutants doubled the cytosol/nuclear ratio of TDP-43 over that seen in wild-type cells. Recent work suggests TDP-43s toxicity stems from its localization to mitochondria (Jul 2016 news). Indeed, under the influence of CHCHD10 mutants, nearly half of the cytosolic TDP-43 deposited inmitochondria.
TDP-43 (red) normally resides in the nucleus but in NIH3T3 mouse fibroblasts expressing R15L or S59L CHCHD10 mutations (second and third rows), it leaches into the cytoplasm, where it localizes with the mitochondrial outer membrane protein TOM20 (green). [Courtesy of DavidKang.]
The CHCHD10 variants also enhanced TDP43 toxicity. Adenovirus-mediated expression of TDP-43 in the brains of young mice caused synaptic markers to drop by 50 and 39 percent in the dentate gyrus and CA3 region of the hippocampus, respectively. Co-expression of CHCHD10 prevented the decline, and expression of either mutant exacerbated it. The results establish that CHCHD10 mutations influence toxicity of TDP43 in neurons, however, the researchers have yet to test this in motor neurons or cortical neurons, the cell types affected in ALS orFTD.
While the work connects CHCHD10 to TDP-43, many questions remain. How does CHCHD10 influence where TDP-43 localizes, and why do the mutations cause TDP-43 to appear in the cytoplasm? Co-immunoprecipitation hinted that CHCHD10 and TDP-43 physically associate, but that mutations do not disrupt this interaction. We have to work out the details, Kang said, noting that their next studies will focus on the mechanisms of CHCHD10 and TDP-43 translocations and theirregulation.
The second report details how a newly discovered ALS variant in UBQLN4 disrupts a different and equally fundamental homeostatic mechanismthe regulated recycling of proteins via the ubiquitin proteasome system. Ubiquilins deliver proteins to the proteasome. UBQLN1 and UBQLN2 are linked to Alzheimers disease and FTD/ALS, but this is the first time UBQLN4 variants have been linked to disease. Ma worked with coauthor Teepu Siddique, whose lab identified the variant through targeted gene sequencing in 267 familial and 411 sporadic ALS cases. One patient carried the single amino acid change, from aspartate to alanine at position 90. None of 332 in-house controls, or more than 60,000 people in a sequencing consortium database, had the change, suggesting it may be the pathogenicvariant.
To test this, first author Brittany Edens expressed wild-type or D90A UBQLN4 in cultured mouse spinal cord neurons, and found the mutant increased neurite number. In zebrafish embryos, the mutant induced abnormal motor neuron branching as well. These morphological effects accompanied inhibition of the proteasome and upregulation of -catenin, one of UBQLN4s target proteins and an important regulator of neuronal development. Treatment with the -catenin inhibitor quercetin reversed the mutant effects on morphology in neurons andzebrafish.
This is an interesting first report linking UBQLN4 to ALS, said Lihong Zhan of the University of California, San Francisco, who was not involved with the work. Zhan told Alzforum hed like to see how the mutation behaves in models more relevant to ALS, such as age-related neuron death. Ma agreed that the models are mainly developmental, but considers them still relevant for ALS, as early life events may render the neurons vulnerable later. The models used in the study were short-term expression systems; Ma told Alzforum they are now working on additional models that will enable a more thorough examination of the mutants impact across the lifespan. He hopes that -catenin, or other substrates of UBQNL4, could become useful therapeutic targets in ALS.Pat McCaffrey
No Available Comments
To make a comment you must login or register.
No Available Further Reading
More:
ALS/FTD Genes Reveal Pathways to Pathology - Alzforum
- BENITEC BIOPHARMA INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q) - Marketscreener.com - February 13th, 2023 [February 13th, 2023]
- CENTOGENE to Participate in Upcoming Conferences in February in the Lead Up to Rare Disease Day - Marketscreener.com - February 7th, 2023 [February 7th, 2023]
- Gene | Definition, Structure, Expression, & Facts | Britannica - January 27th, 2023 [January 27th, 2023]
- New gene therapy delivers treatment directly to brain - January 27th, 2023 [January 27th, 2023]
- Indian Pharma Congress: Gene-cell therapy, preventive medicine future of health care, says expert - Economic Times - January 25th, 2023 [January 25th, 2023]
- A blood test that identifies people at higher risk of miscarriage? Thats the goal of this award-winning Rutgers med student. - The Philadelphia... - January 19th, 2023 [January 19th, 2023]
- Gene Therapy: Genes As Medicine | Pfizer - January 6th, 2023 [January 6th, 2023]
- How Genomics will ensure a risk-free and beneficial treatment for good health and well-being - The Financial Express - December 28th, 2022 [December 28th, 2022]
- Regenerative Medicine Advanced Therapy Designation | FDA - December 18th, 2022 [December 18th, 2022]
- 3576 - Gene ResultCXCL8 C-X-C motif chemokine ligand 8 [ (human)] - November 23rd, 2022 [November 23rd, 2022]
- Study identifies new gene that drives colon cancer - EurekAlert - October 17th, 2022 [October 17th, 2022]
- Updated Stroke Gene Panels: Rapid evolution of knowledge on monogenic causes of stroke | European Journal of Human Genetics - Nature.com - October 17th, 2022 [October 17th, 2022]
- The challenges of translating CRISPR to the clinic - Labiotech.eu - October 17th, 2022 [October 17th, 2022]
- Editas Medicine Presents Preclinical Data on EDIT-103 for Rhodopsin-associated Autosomal Dominant Retinitis Pigmentosa at the European Society of Gene... - October 17th, 2022 [October 17th, 2022]
- 'We have to find a way': FDA seeks solutions to aid bespoke gene therapy - BioPharma Dive - October 17th, 2022 [October 17th, 2022]
- Mathematical model could bring us closer to effective stem cell therapies - Michigan Medicine - October 17th, 2022 [October 17th, 2022]
- Approval, Commercialization Highlighted at Cell & Gene Meeting on the Mesa - Genetic Engineering & Biotechnology News - October 17th, 2022 [October 17th, 2022]
- CANbridge-UMass Chan Medical School Gene Therapy Research in Oral Presentation at the European Society of Gene and Cell Therapy (ESGCT) 29th Annual... - October 17th, 2022 [October 17th, 2022]
- Depression Treatment: How Genetic Testing Can Help Find the Right Medication - Dunya News - October 17th, 2022 [October 17th, 2022]
- The Risk-Reward Proposition for CGT Clinical Trials - Applied Clinical Trials Online - October 17th, 2022 [October 17th, 2022]
- Precision Medicine Could Get Even More Precise With Allarity Therapeutics Next-Generation Diagnostics - Benzinga - October 17th, 2022 [October 17th, 2022]
- Decibel Therapeutics Receives FDA Clearance of IND Application for DB-OTO, a Gene Therapy Product Candidate Designed to Provide Hearing to Individuals... - October 17th, 2022 [October 17th, 2022]
- Time for your medicine: unlocking the power of our body clocks - The Guardian - October 17th, 2022 [October 17th, 2022]
- Replay establishes distinguished Scientific Advisory Board of genomic medicine and cell therapy experts - Yahoo Finance - October 17th, 2022 [October 17th, 2022]
- Scientists Reappraise the Role of Zombie Cells That Anti-aging Medicine Has Sought to Eliminate - Neuroscience News - October 17th, 2022 [October 17th, 2022]
- Forge Biologics Announces Updated Positive Clinical Data in RESKUE, a Novel Phase 1/2 Gene Therapy Trial for Patients with Krabbe Disease - Business... - October 17th, 2022 [October 17th, 2022]
- Gene Expression Signatures Are Analyzed for Biomarkers of Response in HCC - Targeted Oncology - October 17th, 2022 [October 17th, 2022]
- NHS England World-first national genetic testing service to deliver rapid life-saving checks for babies and kids - NHS England - October 17th, 2022 [October 17th, 2022]
- The proteinprotein relationship that could mend a broken heart - RegMedNet - October 17th, 2022 [October 17th, 2022]
- Study finds microprotein correlated to Alzheimers risk - Daily Trojan Online - October 11th, 2022 [October 11th, 2022]
- Passage Bio Announces Appointment of William Chou, M.D. as Chief Executive Officer - Yahoo Finance - October 11th, 2022 [October 11th, 2022]
- Gene Therapy Rapidly Improves Night Vision in Adults with Congenital Blindness - Newswise - October 11th, 2022 [October 11th, 2022]
- Scientists Discover Protein Partners that Could Heal Heart Muscle | Newsroom - UNC Health and UNC School of Medicine - October 11th, 2022 [October 11th, 2022]
- The Pros and Cons of Lentiviral and Adeno-Associated Viral Vectors - The Medicine Maker - October 11th, 2022 [October 11th, 2022]
- Insights & Outcomes: Foreign DNA, quantum potholes and relapsing fever - Yale News - October 11th, 2022 [October 11th, 2022]
- Expediting IND applications with drug master files - BioPharma Dive - October 11th, 2022 [October 11th, 2022]
- UNC School of Medicine Awarded $3 Million to Lead Study to Reduce PTSD Frequency, Severity | Newsroom - UNC Health and UNC School of Medicine - October 11th, 2022 [October 11th, 2022]
- Lineage to Present at Alliance for Regenerative Medicine 2022 Cell & Gene Meeting on the Mesa - businesswire.com - October 8th, 2022 [October 8th, 2022]
- The Next Crispr Gene Editing IPO Could Be Near - Henry Herald - October 8th, 2022 [October 8th, 2022]
- 10-year CRISPR anniversary: How gene editing revolutionized medicine, and what lies ahead - Genetic Literacy Project - October 8th, 2022 [October 8th, 2022]
- Blood from a baby at birth can be gene sequenced to prevent diseases - USA TODAY - October 8th, 2022 [October 8th, 2022]
- What doctors wish patients knew about breast-cancer prevention - American Medical Association - October 8th, 2022 [October 8th, 2022]
- Growth in Cell and Gene Therapy Market - Pharmaceutical Technology Magazine - October 8th, 2022 [October 8th, 2022]
- Gene Editing Service Market 2022 : Top Players to Reflect Impressive Growth Rate till 2029: Caribou Biosciences, CRISPR Therapeutics, Merck KGaA,... - October 8th, 2022 [October 8th, 2022]
- Tip Sheet: $78 million to support new precision oncology institute, update on experimental gene therapy for herpes and the launch of Fred Hutch's new... - October 8th, 2022 [October 8th, 2022]
- Cell and Gene Therapy: Rewriting the Future of Medicine - Technology Networks - October 2nd, 2022 [October 2nd, 2022]
- Growth in Cell and Gene Therapy Market - BioPharm International - October 2nd, 2022 [October 2nd, 2022]
- CRISPR Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to CTX130 for the Treatment of Cutaneous T-Cell... - October 2nd, 2022 [October 2nd, 2022]
- BioMarin Resubmits Biologics License Application (BLA) for Valoctocogene Roxaparvovec AAV Gene Therapy for Severe Hemophilia A to the FDA - PR... - October 2nd, 2022 [October 2nd, 2022]
- Fighting Breast and Ovarian Cancer With a Lupus Antibody - Yale School of Medicine - October 2nd, 2022 [October 2nd, 2022]
- This gene therapy company is testing new tech to 'switch off' diabetes and obesity with a pill - Euronews - October 2nd, 2022 [October 2nd, 2022]
- Tenaya Therapeutics to Participate in Inaugural Hypertrophic Cardiomyopathy Medical Societys 2022 Scientific Sessions - Yahoo Finance - October 2nd, 2022 [October 2nd, 2022]
- Risk of Alzheimer's dementia may be predicted with help of new tool Washington University School of Medicine in St. Louis - Washington University... - October 2nd, 2022 [October 2nd, 2022]
- Tiny Sea Creature's Genes Shed Light on Evolution of Immunity - UPMC - October 2nd, 2022 [October 2nd, 2022]
- Who will get the call from Stockholm? It's time for STAT's 2022 Nobel Prize predictions - STAT - October 2nd, 2022 [October 2nd, 2022]
- Excision BioTherapeutics Awarded California Institute for Regenerative Medicine (CIRM) Grant to Support Ongoing Phase 1/2 Trial Evaluating EBT-101 as... - October 2nd, 2022 [October 2nd, 2022]
- NeuroVoices: Emma Ciafaloni, MD, on the Vast Expansion of Innovative Approaches to Duchenne Muscular Dystrophy - Neurology Live - October 2nd, 2022 [October 2nd, 2022]
- COVID mRNA Jabs and Testing Kicked Off This Industry of Drug Development: Here's What You Need to Know - The Epoch Times - October 2nd, 2022 [October 2nd, 2022]
- Kidney resident macrophages have distinct subpopulations and occupy distinct microenvironments - University of Alabama at Birmingham - October 2nd, 2022 [October 2nd, 2022]
- Nobel Prize for medicine: the full list of winners - The National - October 2nd, 2022 [October 2nd, 2022]
- The surprising link between circadian disruption and cancer may have to do with temperature - EurekAlert - October 2nd, 2022 [October 2nd, 2022]
- The global live cell imaging market is expected to grow at a CAGR of 8.44% during 2022-2027 - Yahoo Finance - October 2nd, 2022 [October 2nd, 2022]
- Chroma Medicine Announces Formation of Scientific Advisory Board of Global Experts in Gene Editing and Cell and Gene Therapy - PR Newswire - September 20th, 2022 [September 20th, 2022]
- Ring Therapeutics Announces Issuance of U.S. Patent for its Anellovector Compositions - Yahoo Finance - September 20th, 2022 [September 20th, 2022]
- Cholesterol gene mutation: Why would a healthy 27-year-old have severe heart problems? - 69News WFMZ-TV - September 20th, 2022 [September 20th, 2022]
- Gene Therapy for Severe Hemophilia B Could Be More Cost Effective Than Current Treatments - Managed Healthcare Executive - September 20th, 2022 [September 20th, 2022]
- AVROBIO Receives Rare Pediatric Disease Designation from U.S. Food and Drug Administration (FDA) for First Gene Therapy in Development for Cystinosis... - September 20th, 2022 [September 20th, 2022]
- The Biggest CGT Breakthroughs Through the Eyes of Our 2022 Power List - The Medicine Maker - September 20th, 2022 [September 20th, 2022]
- Leading Virus Researcher to Chair UVA's Department of Microbiology, Immunology and Cancer Biology - UVA Health Newsroom - September 20th, 2022 [September 20th, 2022]
- Work remains on Tay-Sachs and other Ashkenazi genetic disorders J. - The Jewish News of Northern California - September 20th, 2022 [September 20th, 2022]
- Study Shows Genetic Link to Moving to the Beat of Music - Newswise - September 20th, 2022 [September 20th, 2022]
- Viewpoint: In the post Roe v Wade world, what changes should a biology textbook writer make to address the medical repercussions of Dobbs? - Genetic... - September 20th, 2022 [September 20th, 2022]
- Alnylam Receives Approval in Europe for AMVUTTRA (vutrisiran) for the Treatment of Hereditary Transthyretin-mediated (hATTR) Amyloidosis in Adult... - September 20th, 2022 [September 20th, 2022]
- CSL flexes gene therapy muscle with latest drug - Sydney Morning Herald - September 20th, 2022 [September 20th, 2022]
- The MIT Press releases new book on the science of the heart from cardiac expert Dr. Sian Harding - EurekAlert - September 20th, 2022 [September 20th, 2022]
- Global Pharmaceutical Contract Manufacturing Market is projected to reach a market value of US$329.7 Billion in 2032: Visiongain Reports Ltd - Yahoo... - September 20th, 2022 [September 20th, 2022]
- Alzheon Reports Industry-Leading Biomarker, Brain Preservation and Clinical Effects Following 12 Months of Treatment in Phase 2 Trial of Oral ALZ-801... - September 20th, 2022 [September 20th, 2022]
- Do You Have Lung Cancer With An EGFR Mutation? If So, The Drug Tagrisso Might Be Right For You Based On New Results From A 'Practice Changing' Trial -... - September 20th, 2022 [September 20th, 2022]
- Getting rid of unwanted transformed cells: Possible new directions in cancer therapy - EurekAlert - September 20th, 2022 [September 20th, 2022]
- Sven Kili on reconvening with the ISCT - The Medicine Maker - September 14th, 2022 [September 14th, 2022]